Journal article

Why Should Regulators Consider Using Patient Preferences in Benefit-risk Assessment?

Janine A van Til, Maarten J IJzerman

PharmacoEconomics | ADIS INT LTD | Published : 2014

DOI: 10.1007/s40273-013-0118-6

Citation metrics

24Web of Science
26Scopus

Keywords

Conjoint-Analysis
Science & Technology
Perspective
United States Food and Drug Administration
Life Sciences & Biomedicine
United States
Outcomes
Business & Economics
Consumers
Humans
Europe
Pharmacology & Pharmacy
Risk Assessment
Social Sciences
Care
Health Care Sciences & Services
Economics
Drug Therapy
Decision Support Techniques
Drug-Related Side Effects and Adverse Reactions
Health Technology-Assessment
Health Policy & Services
Government Regulation
Patient Preference